Trial Profile

A Phase IIa clinical trial of resveratrol (JNS-115) in patients with Parkinson's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resveratrol (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Apr 2025 According to Jupiter Neurosciences, this trial is on track to begin dosing in Q3 2025.
30 Jan 2025 According to Jupiter Neurosciences, Zina Biopharmaceuticals media release, company announced a strategic partnership with Zina Biopharmaceuticals, LLC to support all aspects of Jupiter's upcoming Phase 2a clinical trial for Parkinson's disease. Under the agreement, Zina will assist with clinical trial protocol design, including pharmacokinetics and biomarkers, regulatory strategy, and trial site selection to facilitate a smooth trial execution and future clinical progression.
10 Dec 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com